Interesting, seems like there main hangups are that you can’t run against a placebo and that the two mdma trials they looked at was possibly biased for mdma (~40% of the participants had already tried mdma, and there was some questioning about bad experiences being discouraged from follow up) and that their focus was not on the therapy aspect of it, which they apparently don’t judge. I guess I get their reasoning, but it stills seems like a waste as mdma isn’t really that dangerous, and they could have at least recommended what needed to be changed to prove that mdma was beneficial.

Maybe see what happens with Australia given they’ve recently approved the use of Mdma for ptsd. Might be some interesting data to emerge.